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Abstract 
Degree project, Program in Medicine 
Pituitary tumors, transsphenoidal surgery and headache - a prospective cohort study 
Agnes Andersson, 2019, Department of Neurosurgery, Sahlgrenska University Hostpital, 
Gothenburg, Sweden 
Background 
Headache is a common symptom in patients with pituitary tumors, yet insufficiently investigated 
with respect to mechanisms and treatment strategies. Headache is currently not an indication for 
surgical tumor resection. 
Objectives 
The objectives of the present study were to investigate the prevalence of headache in patients before 
and six months after endoscopic transsphenoidal surgery, and to study the correlations between 
headache and both patient and tumor characteristics. 
Methods 
Patients with pituitary tumors admitted to Sahlgrenska University Hospital for endoscopic surgery 
were prospectively enrolled in the study. Disability related to headache was quantified 
preoperatively and six months after surgery. Tumor characteristics were collected from medical 
records: tumor size </>1 cm, suprasellar growth, chiasm compression, invasion of cavernous sinus 
and tumor histology. Analyses were conducted in order to identify relationships between 
tumor/patient factors and both headache and headache response to surgery. 
Results 
Out of the 119 patients included in the study preoperatively, disability due to headache was present 
in 35%. Tumor size <1 cm was significantly associated to headache related disability (p=0.016), as 
well as female sex and young age (p=0.018, p<0.001). No significant correlations between 
disability due to headache and tumor histology, cavernous sinus invasion, chiasm compression or 
suprasellar extension were found. Headache data was collected six months postoperatively from 89 
patients. 21 patients reported a lower MIDAS score postoperatively, ten patients out of these 
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experienced full resolution. 18 patients reported deterioration postoperatively. Looking at patients 
with baseline headache disability alone (n=31), a significantly reduced disability grade (p=0.003) 
could be noted. A reduction in headache related disability was found to be significantly associated 
to tumor size <1 cm (p=0.003). 
Implications 
These results do not support headache as a sole indication for surgery. Further research on pituitary 
microadenomas headache-causing mechanisms and possible resolution through surgery is 
motivated. 
Key words 








Abbreviations used in this thesis 
PG = Pituitary Gland 
PA = Pituitary Adenoma 
NFPA = Non Functioning Pituitary Adenoma 
TTH = Tension Type Headache 
MIDAS = Migraine Disability Assessment 
HIT-6 = Headache Impact Test 
GoPT = Gothenburg Pituitary Tumor study  
TSS = Transsphenoidal surgery 
GH = Growth Hormone 
TSH = Thyreoptropin Stimulating Hormone 
LH = Luteineizing Hormone 
FSH = Follicle-stimulating Hormone 
ACTH = Adenocorticotroph Hormone 
PRL = Prolactinoma 
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Introduction 
Pituitary tumors: prevalence and diagnosis 
 
Pituitary tumors are common intracranial neoplasms with an estimated prevalence of 17% globally. 
This estimation is based on results from postmortem- and radiography studies, with estimates 
ranging from 1%-40%8. The majority of pituitary tumors remain undetected during the patients’ 
lifetime. The global prevalence of diagnosed pituitary tumors is estimated to 0.03-0.05%35. In 
Sweden, with just over 10 million inhabitants, approximately 400 pituitary adenomas (PAs) are 
diagnosed every year and represent 90% of the total occurrences of pituitary tumors26. The 
incidence rate is increasing as a result of more frequent use of MRI (Magnetic resonance imaging). 
Asymptomatic pituitary tumors are, therefore, being detected to a greater extent in patients 
examined with brain imaging for various non-pituitary-related reasons.  
Symptoms of pituitary tumors are related to either hormone abnormalities or compression of 
adjacent structures, such as the optic chiasm, cavernous sinus and the hypothalamus. Typically, 
pituitary tumors grow slowly, and symptoms develop gradually. In few cases, acute neurological 
symptoms develop due to intratumoral bleeding (pituitary apoplexy), causing rapid intrasellar 
expansion23.  
  The pituitary tumors can be either hormone producing or non-functioning.  The most 
common types of pituitary tumors are non-functioning pituitary adenomas (NFPAs) (30%) and 
prolactinomas (30%), followed by growth hormone-producing adenomas (GH)(20%), 
adenocorticotropic hormone-producing adenomas (ACTH)(8%) and thyrotropin- and 
luteinizing/follicle stimulating hormone (TSH, LH, FSH)(1%). The remaining 10% consist of non-
adenomas such as craniopharyngeomas, meningeomas, granulomas, metastatis, cysts etc.26. 
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 Headache in patients with pituitary tumors 
 
Headache is reported in up to 70% of patients with pituitary tumors18. The prevalence of headache 
is consistently higher in patients with growth hormone-producing tumors, prolactinomas and TSH-
producing tumors18,20. The characteristics of headache in patients with pituitary tumors vary, the 
most common being migraine-like headaches and tension type headaches (TTH)6. The same is true 
for the total population32. While migraine-like headaches and TTH do not necessarily occur on 
account of a pituitary mass, the possibility cannot be discarded even in the presence of such a mass. 
If headache arises in the same time frame as the discovery of a pituitary tumor, it might indicate a 
relationship. Other rare types of headaches in these patients are SUNCT (short-lasting, unilateral, 
neuralgiform headache attacks with conjunctival injection and tearing), cluster headache, 
hemicrania continua and pain outside of the trigeminal territory3,16,20.  
Fig. 1 Schematic view of the pituitary gland and its surroundings from a coronary section 
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Theories of headache-causing mechanisms from a pituitary tumor can roughly be divided into two 
categories; physical and biochemical mechanisms. The pituitary gland (PG) sits in a bony pit in the 
skull base called the sella turcica. Laterally, the sella is bordered by the cavernous sinuses through 
which several pain-sensitive structures run, such as the internal carotids and ophthalmic branches of 
the trigeminal nerves. Immediately above the PG, separated from it by the diaphragm sellae, lies the 
optic chiasm21. The PG and its anatomical surroundings are schematically described in Fig. 1. One 
theory of how a brain tumor can physically induce pain is by compressing nerves or innervated 
structures34. Originating from this, cavernous sinus invasion and tumor volume have been the main 
subjects for investigation regarding an eventual causal relationship with headache. Another physical 
theory is that headache is caused by increased intrasellar pressure14. The sella turcica, limited by the 
diaphragm sellae, constitutes its own separated intracranial space where the pressure could be 
affected by internal volume changes.  
The biochemical mechanisms suggested as causes of headache are intratumoral expression 
of substances earlier found to be involved in pain transmission: substance P, Calcitonin gene related 
peptide and pituitary adenylate cyclase activating protein17,37. Dopamine agonist therapy in patients 
with prolactinomas has been observed to cause either headache relief or exacerbation33. This, and 
the observation that somatostatin analogs relieve headache in patients with acromegaly, indicates 
that there is a biochemical mechanism for headaches19.   
Clinical studies of patients with pituitary tumors have found significant correlations between 
headache and family history of headache, young age, female sex, nicotine use and highly 
proliferative tumors (Ki67-labelling index >3%) 18,28,29. In most studies, tumor volume, invasion of 
cavernous sinus, biochemical/neuroendocrine mechanisms and chiasm compression have not been 
shown to be predictors of headaches24,29,36. Gondim et al. suggest in a 2009 study that 
macroadenomas, chiasm compression, cavernous sinus invasion and sellar destruction were all 
associated with headaches12. Wolf. et al. (2016) found the opposite relationship, e.g that 
microadenomas were more prone to headaches36.  
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Most researchers familiar with this area agree that the reason for headache in patients with PA is 
multifactorial, including the patient’s predisposition for headache as well as the physical and 
biochemical properties of the tumor. Size alone is not responsible for the occurrence of headaches. 
Multiple case reports exist, however, where the patients symptoms were trigeminal neuralgia 
ipsilateral to a cavernous sinus invasion and immediate postoperative relief occurred. This supports, 
of course, a pure physical tumor-mechanism causing headache10,11.  
Transsphenoidal tumor extirpation and impact on headaches 
 
Treatments of patients with pituitary tumors require a multidisciplinar approach, with the 
involvement of neurosurgeons, endocrinologists, neuro-ophtalmologists, radiologists, oncologists 
and pathologists26. With the exception of prolactinomas, endoscopic surgery is the standard 
treatment for all symptomatic pituitary tumors. 90% of patients with prolactinomas reach normal 
serum prolactin levels through treatment with dopamine agonists. Other hormone secreting tumors 
are treated medically in cases where surgery is not an option due to comorbidities, or as a 
complement to surgery.  
NFPAs are surgically removed if they grow to affect their surroundings, which usually 
involves compression of the optic chiasm and subsequent visual deterioration 26. When this is not 
the case, watchful waiting with continuous MRIs and visual field examinations is applied33. 
Headache as symptom alone is not an indication for surgery in most patients with pituitary tumors7. 
A few studies exist that are investigating whether transsphenoidal surgery is an effective 
treatment for headaches in these patients. A prospective cohort study on 79 patients with pituitary 
adenomas showed a significant reduction of headache 6 months after transsphenoidal surgery 
(TSS). The same study looking exclusively at the NFPA-patients (n=60) showed that they also had 
significantly reduced headache scores, quantified with HIT-6 (Headache Impact Test, which closely 
resembles MIDAS* in purpose and configuration)27.  A similar study found no significant headache 
reduction in their cohort (n=68)29. A study looking at microadenomas operated with TSS found  
*Migraine Disability Assessment 
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85% of patients experienced headache relief and resolution in 58%9. 
In conclusion, some research has been conducted in order to investigate the prevalence, 
character, mechanisms and treatment effects regarding headache in patients with pituitary tumors. 
The results are inconclusive and do not constitute a sufficient basis for treatment guidelines. Most 
researchers mention the necessity of larger scale prospective studies in order to shed light on what 
position headache should take in evaluating and treating patients with pituitary tumors. 
Aim 
 
The aim of this study is to analyze the prevalence of headache among patients scheduled for 
transsphenoidal resection of a pituitary tumor. Also, to see whether headache is more likely to be 
present in any specific patient category, depending on some tumor or patient characteristic. Finally, 
the aim is to find out if transsphenoidal resection relieves headache in these patients, or to identify a 
subgroup of patients where having headache as an indication for surgery might be appropriate.  
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Methods 
 
The data was derived from the Gothenburg Pituitary Tumor study (GoPT), a prospective study that 
enrolls patients scheduled for pituitary surgery at Sahlgrenska University Hospital, sole provider of 
neurosurgical services for 1.8 million people in the western region of Sweden. Between September 
2015 and April 2019, 119 patients were enrolled in the study. Patients’ headache data (MIDAS 
questionnaire) was collected preoperatively and at a 6 months follow up. Data of 89 patients was 
available on both stages of collection. Six patients answered the first five questions but not question 
6a and 6b (Appendix 1). Three patients were excluded due to inadequate tumor histology, namely 
chordoma, lymphoma and unclear. Fig 2 illustrates the loss of patients from the different stages of 
data collection. 
 





Headache data was quantified using the MIDAS (Migraine Disability Assessment) questionnaire 
(Appendix 1). It consists of two parts (1: questions 1-5, 2: questions 6a and 6b). The first five 
questions address disability due to headache. The scores represent days where the patient 
completely or partly did not participate in normal daily activities due to headache. The total score 
can be used to grade the patients’ disability caused by headache. The questions 6a and b cover how 
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Variables extracted from the MIDAS questionnaire were MIDAS score (0-270) as well as the 
answers from questions 6a and 6b. The MIDAS score is the number of days collected from 
questions 1-5, ignoring 6a and 6b. Questions 6a (0-90) and 6b (0-10) were analyzed separately.  
The MIDAS score is traditionally used to grade the patients disability from I: little/no 
disability (0-5) to IV: severe disability (>20). In this study, a fifth grade was added to separate “no 
disability” from “little disability”. The disability from headache will henceforth be graded as 
described in Table 1. 




Tumor and patient characteristics 
 
The tumor type was determined according to the result of the histopathological analysis performed 
on extirpated tumor mass. The following tumor characteristics were retrospectively collected from a 
radiologist or my own assessments of preoperative MRIs, and documented as present or absent: 
suprasellar extension, chiasm compression and invasion of cavernous sinus. Tumor size was 
classified as <1 cm or >1 cm in diameter as it represents the boundary where microadenomas are 
separated from macroadenomas. As non-adenomas were also classified using these measurments, 
tumor size is not referred to as micro- or macroadenoma. 
 Sex was recorded as female/male. Age was recorded and divided into the categories <45, 
46-60, 61-70, and 71-85 for the analyses. 
 
  
Disability Definition Midas Score 
0. No disability 0. 
I Little disability 1-5 
II Mild disability 6-10 
III Moderate disability 11-20 
IV Severe disability 21+ 
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Statistical analyses 
 
All data was analyzed in Microsoft Excel 14.6.1 and IBM SPSS version 25.0.0.0. Descriptive 
statistical methods, such as cross tables and charts, were used for the analysis of all patient data, as 
well as the comparisons between categories and of the headache severity over time. The Wilcoxon 
signed rank test was used to test for significance of difference in headache data over time. All 
categorical variables were tested for correlations using Chi-squared tests. A model for the likelihood 
of headache was derived through logistic regression. The probability of headache, depending on 
observations x1, x2 , was calculated using the following formula: p = 1-(1/(1+exp(β0+ β1*x1- β2*x2)), 
where β0, β1, β2 are coefficients given by the logistic regression model. 
Ethics  
 
Longitudinal patient data was collected as part of the GoPT-study approved by the Ethical Review 
Board in Gothenburg, Sweden, and conducted according to the 1964 Declaration of Helsinki. All 
patients included in this study have signed an informed consent to their medical records being used 
for research purposes. All data was depersonalized in the analyses. 
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Results 
Table 2 Patient characteristics at baseline, n=119. 
Patient and tumor characteristics contributing to 
headache that negatively affects daily life 
 
72 patients (62%) reported experiencing headache at least 
once in the three months prior to surgery (MIDAS 
question 6a). 42 patients (35%) reported headache related 
disability, defined as a MIDAS score >0. This means that 
at least for one day in the three months prior to surgery, 
productivity in normal daily activities was reduced or lost 
due to headache.  
There was no statistically significant correlation between 
suprasellar extension, compression of the optic chiasm, 
invasion of the cavernous sinus, hormone production, 
tumor histology (Fig. 3) and disability deriving from 
headache (Table 3). Tumor size <1 cm was significantly 
associated with disability from headache (p=0.016) as 
well as with hormone production (p<0.001). There was, 
however, no significant correlation between disabling 
headache and hormone producing tumors (p=0.159). 
66.8% of patients with tumor size <1 cm had headache 
related disability compared to 31.8% of patients with 
tumor size >1 cm (Fig. 4). 
Statistically significant correlation between 
female sex and disabling headache (p=0.018) as well as 
between younger age and disabling headache (p <0.001) 
was found.  
Characteristic Value (%) 
Mean age, range 58 ± 15, 19-85 
Sex  
          Female 59 (49.6) 
          Male 60 (50.4) 
Tumor characteristics  
          <1 cm 12 (10.1) 
          >1 cm 107 (89.9) 
    Suprasellar extension 103 (86.6) 
    Chiasm compression 90 (75.6) 
    Invasion of cavernous sinus 86 (72.3) 
Histology  
Non functioning      
pituitary adenoma 
77 (64.7) 
          Growth hormone 17 (14.3) 
          Corticotrophin 7 (5.9) 
          Craniopharyngeoma 6 (5.0) 
          Prolactinoma 3 (2.5) 
          Other* 9 (7.4) 
Disability based on MIDAS score 
0         0: no disability 77 (64.7) 
1-5      I: little disability  6 (5.0) 
6-10    II: mild disability 4 (3.4) 
11-20  III: moderate disability 4 (3.4) 
>20     IV: severe disability 28 (23.5) 
6a. On how many days in the last 3 months did you 
have a headache? 
0 days 44 (38%) 
1-90 days 72 (62%) 
6b. On a scale of 0 - 10, on average how painful 
were these headaches? 
Median (IQR) 3 (5) 
 IQR = Interquartile range 
*Langerhans cell, Oncocytoma, Pituicytoma, TSH, 
Cyst 
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A logistic regression model was made including sex (male=0, female=1) and tumor size (0=<1 
cm1=>1 cm) as independent variables.  These were the only predictor variables without collinearity 
with each other and simultaneous presence of (χ2) correlation to the outcome variable. The 
dependent variable was headache related disability (no=0, yes=1). Between 8.2 and 11.2% of 
variance in the dependent variable could be explained by this model. The percentage of accuracy in 
the classification was 68.1%. The logistic regression model was significant: χ2(2, n=119)=10.15, 
p=0.006. It gives a female with a tumor <1 cm a 73.2% probability of disabling headache whereas a 
male with a tumor >1cm in size has a probability of 22.9%.  
Among the NFPAs (n=77), one tumor (1.3%) respected the diaphragm sella and was <1 cm 
in size. Six tumors (7.8%) did not compress the optic chiasm. Analyzing NFPAs alone, disabling 
headache was significantly associated with tumors not compressing the optic chiasm (p=0.04). 
Fig. 3 Distribution of headache related disability according to tumor histology. 












I: Little disability 
II: Mild disability 
III: Moderate disability 
IV: Severe disability 
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26% of patients with chiasm compressing NFPAs suffered from headache related disability 
compared to 66.7% of patients with non-chiasm compressing NFPAs (Fig. 5). Suprasellar tumor 
growth, invasion of the cavernous sinus and tumor size (</>1 cm) had no significant association to 
disabling headache (Table 3). 
Transsphenoidal surgery effect on headache related disability 
 
89 patients completed the MIDAS questionnaires both preoperatively and on a six months follow 
up. 31 patients (34.8%) reported disability due to headache preoperatively. By the six months 
follow up, 29 patients (32.5%) claimed headache related disability. Of the patients with disabling 
headache preoperatively, ten patients reported resolution (score=0) at the six months follow up. Ten 
patients had a worsened score and another 11 experienced relief but not resolution. Eight patients 
with no disability from headache preoperatively reported disability from headache at the follow up. 
In conclusion, 21 patients had an improved MIDAS score with a total decrease of 445 days whereas 
18 patients worsened by a total of 335 days. Neither the difference in the disability grade nor the 




























































































Fig. 4 Distribution of headache related disability 
according to tumor size </> 1cm 
 
Fig. 5 Relationship between headache related 
disability and chiasm compression in patients with 
non functioning pituitary adenoma 
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Table 3 Distribution of patients with or without disability from headache according to tumor 
histology, hormone production yes/no, size </>1 cm, chiasm compression, suprasellar growth, 
invasion of the cavernous sinus, sex and age. n=119. 
Tumor 
characteristic n 
(%within tumor c.) 
n= No disability 
(MIDAS 
score=0) 
Headache related disability 
(MIDAS score>0) 




77 54 (70.1%) 23 (29.9%) 0.468. 
 
Corticotroph 7 3 (42.9%) 4 (57.1%) 
Growth Hormone 17 10 (58.8%) 7 (41.2%) 
Craniopharyngeoma 6 3 (50%) 3 (50.0%) 
Prolactinoma 3 1 (33.3%) 2 (66.7%) 
Other 9 6 (66.7%) 3 (33.3%) 
Not hormone 
producing 
91 62 (68.1%) 29 (31.9%) 0.159. 
 
Hormone producing 28 15 (53.6%) 13 (46.4%) 
No invasion of 
cavernous sinus 




86 59 (68.6%) 27 (31.4%) 
Size <1 cm 12 4 (33.3%) 8 (66.7%) 0.016. 
 Size >1 cm 107 73 (68.2%) 34 (31.8%) 
No suprasellar 
growth 
16 7 (43.8%) 9 (56.3%) 0.059. 
 
Suprasellar growth 103 70 (68%) 33 (32%) 
No chiasm 
compression 
28 14 (50%) 14 (50%) 0.052. 
Chiasm 
compression 
90 63 (70%) 27 (30%) 
Female sex 59 32 (54.2%) 27 (45.8%) 0.018. 
Male sex 60 15 (25%) 45 (75%) 
Age <45 years 26 9 (34.6%) 17 (65.4%) <0.001. 
Age 46-60 years 36 19 (53.8%) 17 (47.2%) 
Age 61-70 years 30 25 (83.3%) 5 (16.7%) 
Age 71-85 years 27 24 (88.9%) 3 (11.1%) 
 
MIDAS = Migraine disability assessment 
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Table 4 Only non functioning pituitary adenomas: Distribution of patients with or without disability 
due to headache by patient and tumor characteristics. n=77. 
Tumor/patient 
characteristic 





Pearson Chi-Square sig. 
p= 
No invasion of 
cavernous sinus 
12 7 (58.3%) 5 (41.7%) 0.306. 
Invasion of 
cavernous sinus 
63 46 (73%) 17 (27%) 
Size <1 cm 1 0 (0%) 1 (100%) 0.123. 
Size >1 cm 76 54 (71.1%) 22 (28.9%) 
No suprasellar 
growth 
1 0 (0%) 1 (100%) 0.123. 
Suprasellar 
growth 
76 54 (71.1%) 22 (28.9%) 
No chiasm 
compression 
6 2 (33.3%) 4 (66.7%) 0.040. 
Chiasm 
compression 
71 52 (73.2%) 19 (26.8%) 
Female 37 22 (59.5) 15 (40.5%) 0.049. 
Male 40 32 (80%) 8 (20%) 
<45 years 11 5 (45.5%) 6 (54.5%) 0.004. 
46-60 years 22 11 (50%) 11 (50%) 
60-70 years 21 17 (81% 4 (19%) 
71-85 years 23 21 (91.3%) 2 (8.7%) 
MIDAS = Migraine disability assessment 
Looking at patients with baseline disability (score >0) alone (n=31), a significantly reduced 
disability grade (p=0.003) could be noted (Fig. 6). The score, however, was not significantly 
reduced (p=0.09). Looking at patients with NFPAs or hormone producing adenomas separately, 
neither group had a significantly reduced MIDAS score or grade. 
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Fig. 7 Difference in headache frequency and intensity six months after transsphenoidal surgery, by 
tumor histology 












Preoperatively 6 month follow up 
0: No disability 
I: Little disability 
II: Mild disability 
III: Moderate disability 
IV: Severe disability 
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Transsphenoidal surgery effect on headache frequency and intensity 
 
83 patients answered MIDAS questions 6a and 6b regarding headache frequency and average 
intensity preoperatively and at the six months follow up. 29 patients (34.9%) reported 0 days 
headache whereas seven patients (8.4%) reported 90 days (meaning headache every single day). On 
the six months follow up, 31 patients (37.3%) reported zero days of headache and four (4.8%) 
reported 90 days. The median frequencies were 5 (30)* and 3 (10) respectively, and significantly 
reduced (p=0.013). Headache intensity was not significantly reduced: median preoperative 3 (6)* 
and on follow up 2 (5) (on a scale of 0-10). These results are plotted in Fig. 7. 
*Interquartile range, IQR 
Relation between postoperative reduced headache and tumor characteristics 
 
Reduced headache frequency and intensity (visualized in the lower left quadrant of Fig. 7) did not 
significantly correlate to either compression of optic chiasm, tumor size <1 cm, suprasellar growth, 
invasion of the cavernous sinus or tumor histology. Reduced headache related disability defined as 
a lower MIDAS score correlated with tumor size <1 cm (p=0.003) (Fig. 8) and tumors not 
compressing the optic chiasm (p=0.047). No significant association between a lower MIDAS score 
and suprasellar growth, hormone producing tumors, tumor histology, nor invasion of the cavernous 












































Fig. 8 Relationship between reduced headache related disability and 
tumor size </> 1cm 
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Table 5 Improved (n=21) versus worsened (n=18) or unchanged (n=50) headache related disability 
and patient/tumor characteristics. Chi-squared tests were performed with unchanged and worsened 
patients merged in to one group so as to have a dichotomous variable(0=Improved, 1=Unchanged 
or worsened). 
Tumor characteristic n 









Square sig.  
p= 
Non functioning pituitary 
adenoma 
54 11 (20%) 37 (67.3%) 7 (12.7%) 0.655. 
 
Corticotroph 6 3 (50%) 1 (16.7%) 2 (33.3%) 
Growth Hormone 14 4 (28.6%) 7 (50%) 3 (21.4%) 
Craniopharyngeoma 4 1 (25%) 1 (25%) 2 (50%) 
Prolactinoma 3 1 (33.3%) 1 (33.3%) 1 (33.3%) 
Other 7 1 (14.3%) 3 (42.9%) 3 (42.9%) 
Hormone producing 24 8 (33.3) 10 (41.7%) 6 (25%) 0.202. 
 
Not hormone producing 64 13 (20%) 40 (61.5%) 12 (18.5%) 
Invasion of cavernous sinus 61 12 (19.4%) 39 (62.9%) 11 (17.7%) 0.136. 
 
No invasion of cavernous 
sinus 
26 9 (34.6%) 11 (42.3%) 6 (23.1%) 
Size <1 cm 12 7 (58.3%) 2 (16.7%) 3 (25%) 0.002. 
 Size >1 cm 76 14 (18.2%) 48 (62.3%) 15 (19.5%) 
Suprasellar growth 74 15 (20%) 46 (61.3%) 14 (18.7%) 0.069./ 
 
No suprasellar growth 14 6 (42.9%) 4 (28.6%) 4 (28.6%) 
Chiasm compression 63 11 (17.2%) 41 (64.1%) 12 (18.8%) 0.047./ 
No chiasm compression 24 9 (37.5%) 9 (37.5%) 6 (25%) 
Female 42  12 (28.6%) 19 (45.2%) 11 (26.2%) 0.322. 
Male 46 9 (19.1%) 31 (66%) 7 (14.9%) 
<45 years 24 11 (45.8%) 6 (25%) 7 (29.2%) 0.008./ 
46-60 years 26 6 (23.1%) 13 (50%) 7 (26.9%) 
60-70 years 22 4 (18.2%) 15 (65.2%) 4 (17.4%) 
71-85 years 16 0 (0%) 16 (100%) 0 (0%) 
 
MIDAS = Migraine disability assessment 
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Discussion 
The present study primarily found that patients suffering from headache related disability 
experienced a reduction thereof six months postoperatively. Further, that female patients and 
patients with tumors smaller than 1 cm in diameter had a higher probability of disabling headache 
than their counterparts. It was also observed that the small tumors were associated to postoperative 
improvement of headache to a greater extent.  
Prevalence of headache in the sample compared to the general population 
 
The analysis material at hand was comprised of 119 patients of which 62% reported headaches at 
least once in three months. In a Swedish headache prevalence study performed by SIFO in 2001, 
1668 Swedish people were asked whether they had recurring headaches, to which 62% answered 
with yes4. This result is in line with the findings in our study population (question 6a) (Appendix 1). 
Reviews of global headache prevalence studies show that results are extremely varied. In an article 
published in 2010, reviewing the prevalence of current headaches all over Europe, the mean 
prevalence was calculated to be 53%, with results ranging from 16.7% - 96%22,25,31. Regarding 
patients with pituitary tumors, the headache prevalence’s reports range from 37-70%1,18. Because of 
the inconsistencies in quantification methods, it is not possible to make a credible headache 
prevalence comparison between the general population and patients with pituitary tumors. Further, 
there are currently no means to compare the impact and severity of headache between these 
populations. 
Reasons for more headache related disability in patients with tumors of <1 cm in size 
 
The population in this study was collected from a surgical context. For this reason, merely one of 
the small tumors in the sample were hormone producing. We cannot distinguish between 
hormonal/biochemically derived headache and mass effect from the tumor. Patients with NFPAs 
that did not compress the optic chiasm had, however, significantly more disabling headache 
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compared to patients with NFPAs that compressed the chiasm. This indicates that there is a physical 
component to the relationship between small tumors and headache.  
One of the most accepted theories of how brain tumors give rise to pain is through increased 
intracranial pressure34. In this case, the tumor is situated in the sella turcica, limited cranially by the 
diaphragm sellae. A large tumor has broken these limitations and expands on bigger grounds, 
preventing an increased intrasellar pressure. As long as a tumor is still captured by the cerebral 
membranes lining the sella, the pressure inside (ISP) can build. There are few studies focused on the 
relationship between ISP and headache. Gondim et al. found pituitary adenomas with enlarged and 
intact sellas (Hardy-Vezina class II), to be associated with a much higher ISP compared to tumors 
with either no impact on sella or breaking sellar boundaries13. Baha M Arafah et. al. found a 
significantly higher ISP in patients with headache2 while Pereira-Neto et. al. found no such 
correlation24.    
Intuitively, a faster growing tumor would be more likely to cause a raised ISP. One study 
found highly proliferative tumors (Ki-67%- labeling index >3) to be associated with headache28. 
The clinical implications of this knowledge are, however, not obvious, as proliferation rate is not 
known until postoperatively from tumor samples.  
Surgery as treatment for headaches 
 
We do not know with certainty whether the headaches experienced by the patients in our study were 
attributed to the tumors, latent hereditary and triggered by the tumors, or were not related to the 
tumors at all. Regardless of that, the results of the present study suggest that patients with the 
unfortunate combination of disabling headache and pituitary tumor seem to see relief through 
surgery. Including all patients in the sample, it has to be considered, however, that some patients 
actually worsened in or aquired headache after transsphenoidal resection of the tumor.	The reason 
why some patients experience a worsening in headache six month after surgery is not evident. It 
would be expected that pain secondary to wound healing in the surgical field should not be present 
at that time, but supposing a pituitary mass can trigger migraine in a patient with a latent 
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predisposition, a surgical manipulation in the same area might have the same effect. As in the case 
of preoperative headache, postoperative headache can be assumed to depend on a variety of 
mechanisms. 
Since the patients in this study had indications for surgery in addition to headache, a 
reduction or increase of headache postoperatively can be considered a bonus or “necessary evil”. 
Cumulate results, including ours, reject the hypothesis that a large and invading tumor would be 
more likely to cause headache. This strengthens the incentive to investigate whether headache in 
some cases may be an appropriate indication for surgery, as currently, merely large tumors are 
likely to eventually compress the optic chiasm or pituitary gland, hence providing a ticket to the 
operating room, whereas small tumors are not.  
Choice of headache quantification method 
 
The MIDAS questionnaire was developed in order to monitor symptoms and evaluate treatment 
efficacy in patients with migraine. It is an upgrade of a similar questionnaire called the HIT-630. The 
latter, and to some extent also MIDAS, has been used for quantitative evaluation of headache in 
other patient categories such as the present one, due to the lack of of other alternatives. The 
suitability is questionable. For one, the original grading allows up to five out of 90 days headache-
caused absence from work in the lowest category of disability. This might be acceptable in patients 
with chronic migraine. In case of a disabling headache being a refractory condition caused by 
something else (such as a pituitary tumor), it might, however, not be ideal. Researchers in the area 
of pituitary tumors and headache have mentioned the need of a headache quantification tool 
developed specifically for patients with pituitary tumors5,15. 
Other methodological considerations 
 
As mentioned above, the patients included in the study already had some operation indication. This 
is appropriate when investigating possible headache reduction through surgery. For the evaluation 
of headache severity, prevalence and possible mechanisms causing headache, it would, however, be 
valuable to also include patients with PAs that are not indicative for surgery. 
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The size of the cohort was adequate and the variables analyzed were relevant for the purpose of the 
study. A few of the Chi-squared analyses did not reach the recommended minimum of five patients. 
This is accounted for in tables 3-5.  
 Furthermore, we have not taken into consideration if the surgery within the frame of the 
study was the first, or one out of several reoperations. It is possible that only one follow up was a 
blunt outcome measure, especially with a known high recidivism frequency. 
 Participation in the study was high and the loss of data negligible (Fig. 2). Except for 
MIDAS as headache quantification tool, discussed above, the methods for data collection can be 
assessed as adequate. 
Conclusion 
 
The traditional theories that invasive pituitary tumors would cause headache through compression 
of pain-sensitive structures around the sellae could not be confirmed in the present study. On the 
contrary: our finding suggests that small tumors are associated to headache and reduction of 
headache postoperatively. Further studies could preferably investigate prevalence of headache in 
patients with small pituitary tumors and possible headache-causing mechanisms, such as increased 
intrasellar pressure. More research on whether endoscopic transsphenoidal surgery effectively 
reduces headache in this patient category would also be beneficial.    
Based on the results from this study, headache alone as an indication for surgery can not be 
recommended. Future research, as mentioned above, should have the objective to identify a patient 
type for which headache as an indication for transsphenoidal surgery would be a cost-effective and 
medically justifiable extension to current treatment guidelines.  
Furthermore, the development of a headache quantification tool adapted for patients with 
pituitary tumors would be beneficial, both for future studies and in clinical practice when managing 
headache in these patients.  
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Populärvetenskaplig sammanfattning 
Hypofystumörer, transsphenoidal resektion och huvudvärk – en prospektiv kohortstudie 
 
En av de vanligaste typerna av tumör som drabbar hjärnan är en så kallad hypofystumör. Det är en 
tumör som utgår från eller är lokaliserad vid en liten körtel under hjärnan som kallas för hypofysen. 
Hypofysens uppgift i den friska kroppen är att styra produktionen av hormon från diverse organ. 
Lokalen för hypofysen är väldigt specifik och omgiven av känsliga strukturer som kärl och nerver. 
På grund av hypofysens lokal och funktion kan en liten tumör här ha en kraftig symptombild, 
antingen i form av hormonrubbning eller i typfallet synfältsbortfall för att den trycker på synnerven. 
I den här patientgruppen är det också vanligt med huvudvärk, dock inte klarlagt om det egentligen 
är vanligare än hos normalbefolkningen, och det är mycket svårt att veta om huvudvärken hos en 
sådan här patient beror på en hypofystumör eftersom den ofta ter sig precis som andra “normala” 
huvudvärkstillstånd.  
Den här forskningen syftar till att kartlägga hur vanlig huvudvärk är bland patienter med 
hypofystumör, samt att hitta samband mellan tumör- och patientrelaterade faktorer och huvudvärk. 
Därutöver att utröna om en operation med borttagning av tumören genom näsan hjälper mot 
huvudvärken. I förlängningen skulle sådan kunskap kunna leda till att huvudvärk hos en viss typ av 
patient leder till att man bestämmer sig för att operera patienten. I nuläget är huvudvärk i sig inte en 
indikation för operation, utan det krävs andra symptom från tumören för att man ska välja att 
operera bort den. Den här studien är genomförd på data från 119 patienter som alla har opererat bort 
en hypofystumör med hjälp av titthålsteknik via näsan. Patienternas huvudvärk före och 6 månader 
efter operation har omvandlats till poäng med hjälp av ett frågeformulär som kallas MIDAS. Den 
här datan har jämförts med andra faktorer hos patienten som typ av tumör, storlek på tumör, 
tumörens växtsätt, patientens ålder och kön.  
Resultaten visade att tumörer med en diameter <1 cm i större utsträckning var kopplade till 
huvudvärk än tumörer med diameter >1cm. Det var också patienterna med små tumörer som 
upplevde störst förbättring av operation. Kvinnorna hade svårare huvudvärk än männen. Av de 
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patienter som hade handikappande huvudvärk innan sin operation var det 68% (21 av 31) som blev 
bättre, en statistiskt signifikant förbättring. Såg man på hela gruppen så var förbättringen av 
huvudvärk inte statistiskt signifikant. 18 patienter (20%) var sämre i sin huvudvärk 6 månader efter 
sin operation.  
De här resultaten är relevanta för att de bekräftar vad tidigare studier på området har pekat 
på: att stora tumörer inte ger mer huvudvärk än små. Däremot så verkar det som att patienter med 
små tumörer och huvudvärk kan bli hjälpa av operation. Detta kan vara värt att fortsätta undersöka, 
eftersom att små tumörer med huvudvärk som enda symptom just nu inte behandlas med operation, 
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Appendices 
 
Appendix 1: The MIDAS questionnaire 
 
___1. On how many days in the last 3 months did you miss work or school because of your 
headaches? 
___2. How many days in the last 3 months was your productivity at work or school reduced by half 
or more because of your headaches? (Do not include days you counted in question 1 where you 
missed work or school.) 
 ___3. On how many days in the last 3 months did you not do household work (such as housework, 
home repairs and maintenance, shopping, caring for children and relatives) because of your 
headaches? 
___4. How many days in the last 3 months was your productivity in household work reduced by 
half of more because of your headaches? (Do not include days you counted in question 3 where you 
did not do Household work.) 
___5. On how many days in the last 3 months did you miss family, social or leisure activities 
because of your headaches? 
 
 6 A. On how many days in the last 3 months did you have a headache? (If a headache lasted more 
than 1 day, count each day.) 
6 B. On a scale of 0 - 10, on average how painful were these headaches? (Where 0=no pain at all, 
and 10=pain as bad as it can be.) 
  
 
